Skip to main content
Donna Skerrett, MD, Hematology, New York, NY

DonnaLynneSkerrettMD

Hematology New York, NY

Physician

Dr. Skerrett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Skerrett's full profile

Already have an account?

  • Office

    525 E 68th St
    # 69
    New York, NY 10065
    Phone+1 646-253-2808
    Fax+1 212-746-3856

Education & Training

  • Columbia University
    Columbia UniversityMSC, Public Health-BioStatistics, 2001 - 2003
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1987 - 1989
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 1984 - 1987
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 1984
  • University of Pennsylvania
    University of PennsylvaniaBA, Biology, 1975 - 1979

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1988 - 2026
  • NJ State Medical License
    NJ State Medical License 2003 - 2009
  • American Board of Internal Medicine Internal Medicine
  • American Board of Pathology Blood Banking/Transfusion Medicine

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disea...
    Donna Skerrett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
    Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical TrialOctober 6th, 2022
  • Paradigm Doses First Subjects in Phase III Knee Osteoarthritis Trial
    Paradigm Doses First Subjects in Phase III Knee Osteoarthritis TrialMay 5th, 2022
  • First Subjects Randomized and Dosed in the U.S. Under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OA
    First Subjects Randomized and Dosed in the U.S. Under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OAMay 4th, 2022
  • Join now to see all